All In Biotech

Drug Trial Radar · NCT04937530

RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY

A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Progressive Supranuclear Palsy

Last checked: Nov 19, 2026Latest source record: Jun 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Jun 23, 2021

Primary completion

Jul 30, 2022

Study completion Aug 30, 2022

Sponsor

Lead sponsor
Biojiva LLCIndustry
Sponsor type
Industry
First posted
Jun 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled trial of RT001 in patients with PSP.

Conditions

  • Progressive Supranuclear Palsy

Interventions

  • RT001Drug

    RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months

  • PlaceboDrug

    Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the PSPRS-28 at 48 weeks for the RT001 treated group vs placebo-treated groupTime frame: 48 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Agaharied Teaching Hospital, University of Munich

    Munich, MD, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.